å¦çã®ããããã¤ãæè¿ã¾ã§ãåã¯çããã¨ããã®ã¯åºæ¬çã«ã¤ãããã¨ã ã¨æã£ã¦ãããã¨ãããããã®ã¤ããã®å¤§é¨åãç°¡åã«æ¶ãã¦ãã¾ã£ãã®ã§ãããªãã¨ããããã ã¨ããæå³ã§ä¼ãã¦ã¿ãããé·ãã®ã§èå³ããã£ããèªãã§ãã ããã ä¸å¦çã®ããããããã¤ãä½ã®ã ãããæãã¦ããããè ¹ãå¼±ããä½ãããã¨ä¸ç¢ãã¦ã°ãããå½ç¶å æ°ãªãããããããªããé«æ ¡çã®ãããããã¾ãååããªäººéã§ã¯ãªãã£ããã§ãé å¼µãã°ãªãã¨ããªãã¨æããè¥ãããããã¤ã³ã¹ã¿ã³ãã³ã¼ãã¼ã«ç ç³ãã¶ã¡ã¾ãã¦åå¼·ãããã大å¦ã«ã¯åæ ¼ããã大å¦ã§ã¯å ¸åçãªæ æ°ãªå¦çã§ãèµ·ããã®ã¯ããã©ã«ãã§åå¾ãææ¥ã«ã¯ååãåºã¦ããªãã¨æããç¡æ°åã§ä»ã«ãã¦æãã¨é¬±ç¶æ ã ã£ãã ä½ã¨ãåæ¥ãã¦ITç³»ã«å°±è·ããããããã§ã®ä»äºã®ä»æ¹ã追ããã¦ããã¦ãã£ã¦ãããããªæãã§ããã¤ã綱渡ãããã¦ãããããªæ°åã§å ¨ãä½è£ã¯ãªãã£ããããã§ã20代ã®ãã¡ã¯ãªãã¨ã
第79åæ¯æ¥æ ç»ã³ã³ã¯ã¼ã«ã®ã¢ãã¡ã¼ã·ã§ã³é¨éãããã¥ã¡ã³ã¿ãªã¼é¨éã®ä½åãåéãã¾ãã ã¢ãã¡ã¼ã·ã§ã³é¨éã§ã¯ãè¸è¡çã»å®é¨çã«åªããã¢ãã¡ã¼ã·ã§ã³ä½åã«ã大è¤ä¿¡éè³ããããã¥ã¡ã³ã¿ãªã¼é¨éã®æåªç§ä½åã¯ãããã¥ã¡ã³ã¿ãªã¼æ ç»è³ãã¨ãã¦æ¥å¹´1æã«çºè¡¨ã2æã«è¡¨å½°ãã¾ãã 2024å¹´1æ1æ¥ã12æ31æ¥ã¾ã§ã«å®æãããã¯ä¸æ ããã¢ãã¡ã¼ã·ã§ã³æ ç»ãããã¥ã¡ã³ã¿ãªã¼æ ç»ããã ããã¢ãã¡ã¼ã·ã§ã³é¨éã¯ãå¶ä½ç®çããã¬ãç¨ã®ã¿ã®ä½åã¯é¤ããããã¥ã¡ã³ã¿ãªã¼é¨éã¯ãå¶ä½ç®çããã¬ãç¨ã®ã¿ã®ä½åãä¸æ æéã5åæªæºã®ä½åãå¤å½èªçã®ä½åã¯é¤ãã å¿åãã©ã¼ã ã«å¿ è¦äºé ããè¨å ¥ã®ä¸ãä¸è¨3ç¹ãæ¯æ¥æ ç»ã³ã³ã¯ã¼ã«äºåå±ã¾ã§ãéãä¸ããã â ä½åDVDï¼æï¼Blu-rayãé¤ãï¼ ãã¡ã¤ãã©ã¤ãºæ¸ã¿ã®ãã®ãæ åä½åã®ç»é¢æ¯çã¯ã16ï¼9ãã§è¨å®ãã¦ä¸ããã æ¯çãã4ï¼3ãã®ä½åã¯é»å¸¯ã追å ãã¦ã16ï¼
窪ç°è£½è¬ãã¼ã«ãã£ã³ã°ã¹ã¨ã°ã«ã¼ãä¼ç¤¾ã¯ãã¿ãã¸ã§ã³ã¯ãä¸çä¸ã§ç¼ç¾æ£ã«æ©ãçãã¾ã®è¦åç¶æã¨å復㫠貢ç®ãããã¨ãç®çã«ãã¤ããã¼ã·ã§ã³ããã¾ãã¾ãªå»è¬åã»å»çæ©å¨ã®éçºããã³å®ç¨åã«ç¹ãã¦ã¾ããã¾ãã
å¹´é ã«ãããå ç«æ©è½ã«ãã£ã¦æ²æ» ã§ããæ¥ãè¿ã¥ãã¦ããã®ã§ã¯ã¨å¤¢ãèªã£ãï¼ãããå¾å§ãã®å夢ãå®ç¨è¦æ®ãããå ç«çæ³CARTããéºä¼åã¨ã¯ã½ã¼ã 解æãã西å·ä¼¸ä¸ãåç §ï¼ã ãæ¨å¹´çºè¡¨ãããããã¡ã©æåå容ä½Tç´°èçæ³ï¼Chimera Antigen Receptor T therapyï¼CARTï¼ãã¨ããæè¡ã¨ãå ç«ãå¼±ããã·ã¹ãã ã«å¯¾ããæä½æ²»çãæPD-1ã æPDL-1ãæCTLA4ã¨ããæä½ã«ã¤ãã¦ã®è«æã®çµæã極ãã¦å°è±¡çã§ãæå¾ ãä¸ãã¦ãããããã ã ããã æ£ç´ã«è¨ãã¨ãæä½æ²»çã«ã¤ãã¦ã¯ã©ããã¦ãä»ã®æ¸å¿µãé ããããã ææ°éã®è¬ã¯ã³ã¹ããèª²é¡ çç±ã¯ãã³ã¹ããã ãå¤ãã®ããã«å¹ããã¨ãæããã«ãªã£ãå ´åãï¼åæ°åä¸åããæä½ãé·æéæã¡ç¶ãããã¨ãçµæ¸çã«å¯è½ããä»å¾è°è«ãç¶ãæ°ãããã ãCTLA-4ã¨PD-1ãæ¯ã¹ãã¨ããCTLA-4ã¯è¤éã§çµæ¸æ§ã®å£ãè¶ããã®ã¯å®¹æã§
å ç«åã§ããã¨éãä¼æ¥ã§ããé©æ°çãªå»çæè¡ã»ãµã¼ãã¹ãåµé ããã¿ãªãã¾ã®æªæ¥ã«è²¢ç®ãã¦ããã¾ãã
çªç¶æ¯ãçããªããä¼ç¤¾ããè¿ãã¨ããå®æãªçç±ã§ãä½ã®å£ã³ãã調ã¹ãé©å½ã«éãåºããæ¸è°·å®®çåæ¯ç§ã ä»æ¥ã§è¨4åã®è«æ¯æ²»çãçµãã£ããã ãã©ãUX(ã¦ã¼ã¶ã¼ã¨ã¯ã¹ããªã¨ã³ã¹)ãã¤ããããã®ã§ãæ¯éãç´¹ä»ãããã 1. ã»ã¼å¾ ããªã äºç´ãã¦ãããªããªããã®æééãã«è¦ã¦ããããªãç é¢ã¯å¤ã ããããã©ãããã¯ã»ã¼å¾ ããã«ãããæ²»çããã¦ãããã 2. å¾¹åºçã«ãå£ããªãµã¼ã ååã¯ãã¬ã³ãã²ã³ããå£è åçããå¾¹åºçã«å£å ã調ã¹ä¸ãããããå£å ã®ãã¡ãã¨ææ¡ããé©åãªæ²»çãããããã®ããã ãåå診å¯å¾ã¯ãããå£ã®èª¬ææ¸ãã¨ãããæ¯ä¸æ¬ä¸æ¬ã®ç¾ç¶æ ãäºç´°ãã«æ¸ãããè³æãããããæ¥ãããããããèªåã®ãå£ã®ä¸ã丸裸ã«ãããã 3. ç©ããããã¹ãã¤ã« å çããæ¯ç§å©æããããã¹ãã¤ã«ãç©ãããåºæ¬ã¯ç¬é¡ãã¡ãªã¿ã«ãã¤ã±ã¡ã³æ¯å»è ãããããã 4. ç解深ã¾ãæ¯ã®ã¤ã³ãã©ã°ã©ãã£ãã¯ã ã¼ãã¼ æ²»
æ²¹ã£ãããã®ãçããã®ãªã©ããã¨ãããèãããç¡æ§ã«ââãé£ã¹ããï¼ãã¨æããã¨ã£ã¦ããã¾ããããå®ã¯ãã®æ¿ããææ ã¯ãä½ãç¹å®ã®æ é¤ç´ ã®ä¸è¶³ãç¥ããã¦ãã大äºãªãµã¤ã³ãªã®ã ã¨ãã ã§ããé«ã«ããªã¼é£åãªã©ã®é£ã¹éãã¯ãä½ã«è² æ ãããã¦ãã¾ãã¾ããããã§Monell Chemical Senses Centerã®ãã¼ã·ã£å士ããããããç¡æ§ã«é£ã¹ãããªã£ãããã®æ é¤ç´ ã足ãã¦ããªããªã¹ãããçºè¡¨ãã¾ããã â¼ä»¥ä¸ã¯ããªã¹ããæ¥æ¬èªã«è¨³ãããã® ä¸è¶³ãã¦ããæ é¤ç´ ã¨ã代ããã«é£ã¹ãã¨æ¬²æ±ãåã¾ãé£ã¹ç©ã®ä¾ãè¼ãã¦ãã¾ãã ãã§ã³ã¬ã¼ããç¡æ§ã«é£ã¹ãããªã£ããï¼ åºå ¸ï¼grafvision / iStock. by Getty Images ããã°ãã·ã¦ã ã çãããã»ã·ã¼ãé¡ãè±é¡ãæç© åºå ¸ï¼FotografiaBasica / iStock. by Getty Images çããã®ãç¡
Facebookããµã ã¹ã³ãAppleãªã©ã«ç¶ãã¦ããã«ã¹ã±ã¢æ¥çã¸ã®åå ¥ãè¨ç»ãã¦ãããã¾ãã¯å社ã½ã¼ã·ã£ã«ãããã¯ã¼ã¯ä¸ã®ãªã³ã©ã¤ã³ãµãã¼ãã³ãã¥ããã£ã¼ã®æ§ç¯ããçæããã¨ããã Reutersã¯ç¬å è¨äºã§ãæ¬ä»¶ã«è©³ãã3人ã®æ å ±çã®è©±ã¨ãã¦ãå社ããåãçç¶ãæ±ããFacebookã¦ã¼ã¶ã¼ãã¤ãªããªã³ã©ã¤ã³ããµãã¼ããã³ãã¥ããã£ã¼ããåãçµã¿ãéå§ããã¨å ±ããã ããã«å ãã¦ãå¥ã®ãã¼ã ããäºé²çãªãã¢ããªã±ã¼ã·ã§ã³ã«ãã£ã¦äººã ã®ã©ã¤ãã¹ã¿ã¤ã«ã®æ¹åãæ¯æ´ããæ¹æ³ãæ¤è¨ãã¦ããã¨ããããã®ãããªç¨®é¡ã®ã¢ããªã¯ããMyFitness Palãã¨åããããªãã£ãããã¹ãã«ããªã¼è¿½è·¡ãå«ããããããã¯ãæ é¤ãéåãæåãæ¨å¥¨ãããé£åã«é¢ããã¬ã¤ãã©ã¤ã³ãçºè¡ããå¯è½æ§ãããã Reutersã®æ å ±çãã«ããã¨ãFacebookã¯ããã¾ã§ã®æ°ã«æéã«ããå»çæ¥çã®å°é家ãèµ·æ¥å®¶ãã¨ä¼å
ç§ãã¡ãèãããªãããªãã¼ã·ã§ã³ã¨ã¯ï½¤ã¿ãªããã®çæ´»ãåæ§ç¯ãããã®ï½¡æ£è ãã¾ã¨ãã®ã家æã¨ã®å¿ããã®ãµããã。ãã¼ã å»çã®åä¸ï½¡å°åã¨ã®é£æºã®å¼·å。ããªãããªãã¼ã·ã§ã³ã®å¿æä½ããè¸ã«å»ã¿ï½¤ãããããæè¯ã®å»çãç®æãããã¨æãã¾ã。
⺠2024 ( 276 ) ⺠09/15 - 09/22 ( 7 ) ⺠09/08 - 09/15 ( 8 ) ⺠09/01 - 09/08 ( 7 ) ⺠08/25 - 09/01 ( 8 ) ⺠08/18 - 08/25 ( 7 ) ⺠08/11 - 08/18 ( 8 ) ⺠08/04 - 08/11 ( 8 ) ⺠07/28 - 08/04 ( 7 ) ⺠07/21 - 07/28 ( 7 ) ⺠07/14 - 07/21 ( 8 ) ⺠07/07 - 07/14 ( 7 ) ⺠06/30 - 07/07 ( 7 ) ⺠06/23 - 06/30 ( 7 ) ⺠06/16 - 06/23 ( 7 ) ⺠06/09 - 06/16 ( 7 ) ⺠06/02 - 06/09 ( 7 ) ⺠05/26 - 06/02 ( 7 ) ⺠05/19 - 0
Misfit SmartwatchesMisfit Vapor 2Misfit VaporMisfit CommandMisfit PathMisfit PhaseView AllFitness TrackersMisfit RayMisfit Shine 2Misfit FlareSwarovski Activity CrystalView AllAccessoriesMisfit Vapor 2Misfit VaporMisfit CommandMisfit PathMisfit PhaseMisfit Shine 2Batteries + GearView All Customize Holiday Gift Guide Shop Instagram Support Getting Started Contact Sign in Ship to: Americas United St
ãã«ã¹ã±ã¢ã«é¢ãã人ã¸ãå ¬å¼iBooksï½¢iOS in Healthcareï½£ç»å ´2014.08.14 13:00 ã¢ããã«ã®ãã«ã¹ã±ã¢ã¸ã®æ¬æ°åº¦ã伺ãã¾ãã 次æiOS 8ãããã«ã¹ã±ã¢åéã«æ¬æ ¼é²åºããã¨è¨ããã¦ããã¢ããã«ãããå ¬å¼ã®iBooksï½¢iOS in Healthcareï½£ãç»å ´ãã¾ãããiOSãiPhoneãiPadãå»çç¾å ´ã§å®éã«ã©ã®ããã«ä½¿ããã¦ãããã»å»çæè²ã¸ã®æ´»ç¨ä¾ã»å»çç³»ã¢ããªãªã©ãç´¹ä»ããã¦ãã¾ãã æ´»ç¨ä¾ã®ä¸ã¤ãã¢ã¡ãªã«ã®ã¡ã¤ã¨ã¼ã¯ãªããã¯ã¯ä¸ççã«æåãªç é¢ã§iPhoneãiPadãå°å ¥ãç©æ¥µçã«æ´»ç¨ãã¦ãããã¨ã§ãç¥ããã¦ãã¾ããï½¢iOS in Healthcareï½£ã§ã¯ç é¢ã®ã¹ã¿ãããã¡ã®ã¤ã³ã¿ãã¥ã¼åç»ã交ããªãããã¡ã¤ã¨ã¼ã¯ãªããã¯ãç¬èªéçºããã¢ããªã«ãã£ã¦ããã«å»çãæ£è ã¨ã®ã³ãã¥ãã±ã¼ã·ã§ã³ãæ¹åããã®ãç´¹ä»ããã¦ãã¾ãã ã¡ã¤ã¨ã¼ã¯ãªã
ããã¢ãã¼ã¿ãã¨ã¯ã顧客ã«ä»è ã¨ã®æ¯è¼ã示ããã¼ã¿ãæãããã¢ãã¼ã¿ãåºã«ä»²éã©ããã§åç£ç¢ç£¨ã§ããæ©è½ã製åã»ãµã¼ãã¹ã«çµã¿è¾¼ãã°ã顧客ã®è¡åãå¤ããããå¯è½æ§ãé«ã¾ãããã®åºæ¬çãªæ¹æ³ããäºä¾ã¨ã¨ãã«ãããããã解説ããã æ°ããªè£½åã®æå ¥ã¨ããã®ã¯æ¬è³ªçã«ã人ã ã«è¡åãå¤ããããä¿ãè¡çºã§ãããå¤ãã®ä¼æ¥ã¯ãæ°è£½åã®æ©è½çãªå©ç¹ãå¾æ¥åãããã¯ããã«é åçã§ããã¨ç¤ºããã¨ã§ããããå®ç¾ãããã¨ãã¦ãããã ããã®ã¢ããã¼ãããã¾ããããã¨ã¯ãã£ãã«ãªããçµå±ã®ã¨ãããåã©ãã®é ã«ãéèã®ã»ãããã¶ã¼ããããä½ã«ããã®ããã¨æ¯è¦ªã«è¨ãããã ãã§ãéèã好ãã§é£ã¹ã人ã¯ä½äººããã ãããã ã ããéèãé£ã¹ãã¨ãããããã®ãããªãã®è¦ªåã ã£ããªããããã«åãå ¥ããã®ã§ã¯ãªããããããã¯5å¹´çã®ã¯ã©ã¹ã§ããããã³ãªã¼ãé£ã¹ããã¨ãçªç¶ãã¼ã ã«ãªã£ãã¨ãããï¼ äººã ã®è¡åãå¤åãããæ°è¦ã«ãã´ãª
å¹³ç´ ã¯æ ªå¼ä¼ç¤¾ã©ã¤ããã¢ã®ãµã¼ãã¹ã ãå©ç¨ããã ããããã¨ããããã¾ãã æè¨åãã¥ã¼ã¹ãµã¤ããBLOGOSãã¯ã 2022å¹´5æ31æ¥ããã¡ã¾ãã¦ã ãµã¼ãã¹ã®æä¾ãçµäºãããã¾ããã ä¸é¨ã®ãªãªã¸ãã«è¨äºã«ã¤ãã¾ãã¦ã¯ã livedoorãã¥ã¼ã¹å ã® ãBLOGOSã®è¨äºä¸è¦§ãããã覧ããã ãã¾ãã é·ãããå©ç¨ããã ãããããã¨ããããã¾ããã ãµã¼ãã¹çµäºã«é¢ãããåãåããã¯ã ä¸è¨ã¾ã§ãé¡ããããã¾ãã ãåãåãã
Emerging technology review ã·ãªã³ã³ãã¬ã¼ããã®å 端æè¡åæã¬ãã¼ããå 端æè¡ãå¦ã³ãæ¥æ¬ä¼æ¥ã®çµå¶æ¦ç¥ã¨è£½åè¨ç»çå®ã«å¯ä¸ãæªæ¥ãçã¿åºããã³ãã£ã¼ä¼æ¥ããã¡ã¦ã³ãã¼ã¨æ¥ããã¤ããã¼ã·ã§ã³èªçã®ææ³ã«è¿«ãã âEmerging Technology Reviewâ is research reports featuring the latest technologies. The articles analyze the new wave of the technologies and explores the Silicon Valley culture and innovations. â featured stories ã·ãªã³ã³ãã¬ã¼ããã®å 端æè¡åæã¬ãã¼ã (ããã°ã¸ã®ãªã³ã¯) â about ã·ãªã³ã³ãã¬ã¼ã§çã¾ããå 端æè¡ã解æ VentureCl
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}